$31.06 -1.66 (-5.16%)
Anbio Biotechnology Class A Ordinary Shares (NNNN)
Anbio Biotechnology is a biopharmaceutical company focused on the development and commercialization of innovative therapies, particularly in the fields of cancer treatment and immune modulation. The company emphasizes research and development to bring novel drugs to market, aiming to address unmet medical needs.
Company News
Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System
Anbio Biotechnology launched a Chikungunya IgM/IgG Rapid Test and an AP-100 Ultra-Fast PCR system to support rapid diagnostic testing for infectious diseases, enabling quick detection of pathogens in both centralized and decentralized healthcare settings.